nodes	percent_of_prediction	percent_of_DWPC	metapath
Mifepristone—Musculoskeletal chest pain—Varenicline—nicotine dependence	0.0882	0.0936	CcSEcCtD
Mifepristone—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.0379	0.0402	CcSEcCtD
Mifepristone—Hot flush—Varenicline—nicotine dependence	0.0265	0.0282	CcSEcCtD
Mifepristone—Menopausal symptoms—Varenicline—nicotine dependence	0.0263	0.0279	CcSEcCtD
Mifepristone—Thirst—Varenicline—nicotine dependence	0.0261	0.0277	CcSEcCtD
Mifepristone—Hypoglycaemia—Varenicline—nicotine dependence	0.0254	0.027	CcSEcCtD
Mifepristone—Hypokalaemia—Varenicline—nicotine dependence	0.0226	0.024	CcSEcCtD
Mifepristone—Breast disorder—Varenicline—nicotine dependence	0.0224	0.0238	CcSEcCtD
Mifepristone—Cramp muscle—Varenicline—nicotine dependence	0.0223	0.0237	CcSEcCtD
Mifepristone—Nasopharyngitis—Varenicline—nicotine dependence	0.0222	0.0236	CcSEcCtD
Mifepristone—Infestation NOS—Varenicline—nicotine dependence	0.0191	0.0203	CcSEcCtD
Mifepristone—Infestation—Varenicline—nicotine dependence	0.0191	0.0203	CcSEcCtD
Mifepristone—Sinusitis—Varenicline—nicotine dependence	0.0179	0.019	CcSEcCtD
Mifepristone—Oedema peripheral—Varenicline—nicotine dependence	0.0169	0.018	CcSEcCtD
Mifepristone—Connective tissue disorder—Varenicline—nicotine dependence	0.0169	0.0179	CcSEcCtD
Mifepristone—Angiopathy—Varenicline—nicotine dependence	0.0156	0.0165	CcSEcCtD
Mifepristone—Mediastinal disorder—Varenicline—nicotine dependence	0.0155	0.0164	CcSEcCtD
Mifepristone—Chills—Varenicline—nicotine dependence	0.0154	0.0164	CcSEcCtD
Mifepristone—Mental disorder—Varenicline—nicotine dependence	0.015	0.016	CcSEcCtD
Mifepristone—Malnutrition—Varenicline—nicotine dependence	0.0149	0.0159	CcSEcCtD
Mifepristone—Back pain—Varenicline—nicotine dependence	0.0145	0.0153	CcSEcCtD
Mifepristone—Muscle spasms—Varenicline—nicotine dependence	0.0144	0.0153	CcSEcCtD
Mifepristone—Ill-defined disorder—Varenicline—nicotine dependence	0.0139	0.0147	CcSEcCtD
Mifepristone—Angioedema—Varenicline—nicotine dependence	0.0137	0.0145	CcSEcCtD
Mifepristone—Malaise—Varenicline—nicotine dependence	0.0135	0.0143	CcSEcCtD
Mifepristone—Hypertension—Varenicline—nicotine dependence	0.0129	0.0137	CcSEcCtD
Mifepristone—Myalgia—Varenicline—nicotine dependence	0.0127	0.0135	CcSEcCtD
Mifepristone—Arthralgia—Varenicline—nicotine dependence	0.0127	0.0135	CcSEcCtD
Mifepristone—Anxiety—Varenicline—nicotine dependence	0.0127	0.0135	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.0126	0.0134	CcSEcCtD
Mifepristone—Discomfort—Varenicline—nicotine dependence	0.0126	0.0133	CcSEcCtD
Mifepristone—Dry mouth—Varenicline—nicotine dependence	0.0124	0.0132	CcSEcCtD
Mifepristone—Oedema—Varenicline—nicotine dependence	0.0122	0.0129	CcSEcCtD
Mifepristone—Infection—Varenicline—nicotine dependence	0.0121	0.0129	CcSEcCtD
Mifepristone—Nervous system disorder—Varenicline—nicotine dependence	0.012	0.0127	CcSEcCtD
Mifepristone—Skin disorder—Varenicline—nicotine dependence	0.0118	0.0126	CcSEcCtD
Mifepristone—Anorexia—Varenicline—nicotine dependence	0.0116	0.0123	CcSEcCtD
Mifepristone—Hypotension—Varenicline—nicotine dependence	0.0114	0.0121	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.0111	0.0118	CcSEcCtD
Mifepristone—Insomnia—Varenicline—nicotine dependence	0.011	0.0117	CcSEcCtD
Mifepristone—Dyspnoea—Varenicline—nicotine dependence	0.0109	0.0115	CcSEcCtD
Mifepristone—Somnolence—Varenicline—nicotine dependence	0.0108	0.0115	CcSEcCtD
Mifepristone—Decreased appetite—Varenicline—nicotine dependence	0.0106	0.0113	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Varenicline—nicotine dependence	0.0105	0.0112	CcSEcCtD
Mifepristone—Fatigue—Varenicline—nicotine dependence	0.0105	0.0112	CcSEcCtD
Mifepristone—Constipation—Varenicline—nicotine dependence	0.0104	0.0111	CcSEcCtD
Mifepristone—Pain—Varenicline—nicotine dependence	0.0104	0.0111	CcSEcCtD
Mifepristone—Feeling abnormal—Varenicline—nicotine dependence	0.0101	0.0107	CcSEcCtD
Mifepristone—Gastrointestinal pain—Varenicline—nicotine dependence	0.00997	0.0106	CcSEcCtD
Mifepristone—Urticaria—Varenicline—nicotine dependence	0.00969	0.0103	CcSEcCtD
Mifepristone—Abdominal pain—Varenicline—nicotine dependence	0.00964	0.0102	CcSEcCtD
Mifepristone—Body temperature increased—Varenicline—nicotine dependence	0.00964	0.0102	CcSEcCtD
Mifepristone—Hypersensitivity—Varenicline—nicotine dependence	0.00899	0.00954	CcSEcCtD
Mifepristone—Asthenia—Varenicline—nicotine dependence	0.00875	0.00929	CcSEcCtD
Mifepristone—Pruritus—Varenicline—nicotine dependence	0.00863	0.00916	CcSEcCtD
Mifepristone—Diarrhoea—Varenicline—nicotine dependence	0.00835	0.00886	CcSEcCtD
Mifepristone—Dizziness—Varenicline—nicotine dependence	0.00807	0.00856	CcSEcCtD
Mifepristone—Vomiting—Varenicline—nicotine dependence	0.00776	0.00823	CcSEcCtD
Mifepristone—Rash—Varenicline—nicotine dependence	0.00769	0.00816	CcSEcCtD
Mifepristone—Dermatitis—Varenicline—nicotine dependence	0.00768	0.00816	CcSEcCtD
Mifepristone—Headache—Varenicline—nicotine dependence	0.00764	0.00811	CcSEcCtD
Mifepristone—Nausea—Varenicline—nicotine dependence	0.00725	0.00769	CcSEcCtD
Mifepristone—CYP3A7—Xenobiotics—CYP2A7—nicotine dependence	0.00563	0.0975	CbGpPWpGaD
Mifepristone—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00467	0.0808	CbGpPWpGaD
Mifepristone—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.00407	0.0705	CbGpPWpGaD
Mifepristone—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00364	0.0631	CbGpPWpGaD
Mifepristone—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00289	0.0501	CbGpPWpGaD
Mifepristone—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00234	0.0405	CbGpPWpGaD
Mifepristone—CYP3A7—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00231	0.0399	CbGpPWpGaD
Mifepristone—CYP3A7—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0019	0.0328	CbGpPWpGaD
Mifepristone—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00189	0.0328	CbGpPWpGaD
Mifepristone—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00169	0.0293	CbGpPWpGaD
Mifepristone—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00167	0.0289	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.0014	0.0242	CbGpPWpGaD
Mifepristone—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00137	0.0237	CbGpPWpGaD
Mifepristone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.0012	0.0208	CbGpPWpGaD
Mifepristone—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00119	0.0205	CbGpPWpGaD
Mifepristone—CYP3A7—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00107	0.0185	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00106	0.0183	CbGpPWpGaD
Mifepristone—CYP3A7—Biological oxidations—CYP2A7—nicotine dependence	0.00101	0.0174	CbGpPWpGaD
Mifepristone—CYP3A7—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000993	0.0172	CbGpPWpGaD
Mifepristone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000974	0.0169	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.000932	0.0161	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000846	0.0146	CbGpPWpGaD
Mifepristone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000786	0.0136	CbGpPWpGaD
Mifepristone—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000776	0.0134	CbGpPWpGaD
Mifepristone—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000772	0.0134	CbGpPWpGaD
Mifepristone—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.000728	0.0126	CbGpPWpGaD
Mifepristone—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000718	0.0124	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.000707	0.0122	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000642	0.0111	CbGpPWpGaD
Mifepristone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000637	0.011	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—CCAR1—nicotine dependence	0.000604	0.0104	CbGpPWpGaD
Mifepristone—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000549	0.0095	CbGpPWpGaD
Mifepristone—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000518	0.00896	CbGpPWpGaD
Mifepristone—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000511	0.00884	CbGpPWpGaD
Mifepristone—AR—Gene Expression—CCAR1—nicotine dependence	0.00046	0.00796	CbGpPWpGaD
Mifepristone—ABCC1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000422	0.0073	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—TAS2R16—nicotine dependence	0.000393	0.00679	CbGpPWpGaD
Mifepristone—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000359	0.00621	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—CCAR1—nicotine dependence	0.000349	0.00604	CbGpPWpGaD
Mifepristone—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000338	0.00586	CbGpPWpGaD
Mifepristone—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000334	0.00578	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—FGD1—nicotine dependence	0.000308	0.00533	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—AKR1B10—nicotine dependence	0.000272	0.00471	CbGpPWpGaD
Mifepristone—ABCC1—Disease—AKR1B10—nicotine dependence	0.000254	0.00439	CbGpPWpGaD
Mifepristone—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000201	0.00347	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—CYP2A7—nicotine dependence	0.000197	0.00342	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—WASF2—nicotine dependence	0.000192	0.00332	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—WASF1—nicotine dependence	0.000184	0.00318	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—CYP2A7—nicotine dependence	0.000172	0.00298	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—OPRM1—nicotine dependence	0.000165	0.00286	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000124	0.00215	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—DRD2—nicotine dependence	0.00012	0.00207	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—CYP2A7—nicotine dependence	9.39e-05	0.00163	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—CYP2A7—nicotine dependence	8.85e-05	0.00153	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—CYP2A7—nicotine dependence	5.79e-05	0.001	CbGpPWpGaD
